JP2018534355A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534355A5 JP2018534355A5 JP2018538052A JP2018538052A JP2018534355A5 JP 2018534355 A5 JP2018534355 A5 JP 2018534355A5 JP 2018538052 A JP2018538052 A JP 2018538052A JP 2018538052 A JP2018538052 A JP 2018538052A JP 2018534355 A5 JP2018534355 A5 JP 2018534355A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- methyl
- compound according
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 15
- FVHFOYRHJUFWFT-MRXNPFEDSA-N C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C=1C=NC(=CC=1)C(F)(F)F Chemical compound C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C=1C=NC(=CC=1)C(F)(F)F FVHFOYRHJUFWFT-MRXNPFEDSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000002541 furyl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108010015181 PPAR delta Proteins 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- FMOPHFSPINWSOV-QGZVFWFLSA-N C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)C(F)(F)F Chemical compound C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)C(F)(F)F FMOPHFSPINWSOV-QGZVFWFLSA-N 0.000 claims 1
- GYNMVDMBFKGCCR-QGZVFWFLSA-N C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)OC(F)(F)F Chemical compound C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)OC(F)(F)F GYNMVDMBFKGCCR-QGZVFWFLSA-N 0.000 claims 1
- 206010049565 Muscle fatigue Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- XOFBESNFVYMKTL-HXUWFJFHSA-N O1C(=CC=C1)C1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1 Chemical compound O1C(=CC=C1)C1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1 XOFBESNFVYMKTL-HXUWFJFHSA-N 0.000 claims 1
- 208000014245 Ocular vascular disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000012268 mitochondrial disease Diseases 0.000 claims 1
- 230000008555 neuronal activation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238629P | 2015-10-07 | 2015-10-07 | |
| US62/238,629 | 2015-10-07 | ||
| US201562243263P | 2015-10-19 | 2015-10-19 | |
| US62/243,263 | 2015-10-19 | ||
| US201662352348P | 2016-06-20 | 2016-06-20 | |
| US62/352,348 | 2016-06-20 | ||
| PCT/US2016/055521 WO2017062468A1 (en) | 2015-10-07 | 2016-10-05 | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020016147A Division JP6866514B2 (ja) | 2015-10-07 | 2020-02-03 | Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534355A JP2018534355A (ja) | 2018-11-22 |
| JP2018534355A5 true JP2018534355A5 (enExample) | 2019-11-14 |
| JP6657413B2 JP6657413B2 (ja) | 2020-03-04 |
Family
ID=57200096
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538052A Active JP6657413B2 (ja) | 2015-10-07 | 2016-10-05 | Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法 |
| JP2020016147A Active JP6866514B2 (ja) | 2015-10-07 | 2020-02-03 | Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020016147A Active JP6866514B2 (ja) | 2015-10-07 | 2020-02-03 | Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US10399958B2 (enExample) |
| EP (3) | EP3770146B1 (enExample) |
| JP (2) | JP6657413B2 (enExample) |
| KR (2) | KR102667386B1 (enExample) |
| CN (3) | CN113004205B (enExample) |
| AU (3) | AU2016333963C1 (enExample) |
| BR (1) | BR112018006866B1 (enExample) |
| CA (1) | CA3000431A1 (enExample) |
| CO (1) | CO2018004473A2 (enExample) |
| DK (1) | DK3359528T3 (enExample) |
| EA (1) | EA037371B1 (enExample) |
| ES (3) | ES2949852T3 (enExample) |
| HU (1) | HUE058154T2 (enExample) |
| IL (3) | IL258225B (enExample) |
| JO (3) | JO3738B1 (enExample) |
| MA (2) | MA52648A (enExample) |
| MX (3) | MX392524B (enExample) |
| MY (1) | MY203081A (enExample) |
| PH (1) | PH12018500762A1 (enExample) |
| PL (1) | PL3359528T3 (enExample) |
| PT (1) | PT3359528T (enExample) |
| SG (1) | SG10201906400SA (enExample) |
| TW (3) | TWI742479B (enExample) |
| UA (1) | UA122237C2 (enExample) |
| WO (1) | WO2017062468A1 (enExample) |
| ZA (4) | ZA201802029B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037371B1 (ru) * | 2015-10-07 | 2021-03-19 | Митобридж, Инк. | Агонисты ppar, соединения, фармацевтические композиции и способы их применения |
| US11358954B2 (en) | 2016-04-13 | 2022-06-14 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| ES2859487T3 (es) * | 2016-10-05 | 2021-10-04 | Mitobridge Inc | Métodos para tratar las lesiones renales agudas |
| ES2887008T3 (es) | 2016-10-05 | 2021-12-21 | Mitobridge Inc | Formas cristalinas y de sal de compuestos agonistas del PPAR |
| US20220331267A1 (en) * | 2019-09-05 | 2022-10-20 | Rush University Medical Center | Methods and compositions for treatment of demyelinating disorders |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| MX2023010537A (es) * | 2021-03-08 | 2023-11-28 | Abionyx Pharma Sa | Compuestos útiles para tratar enfermedades del hígado. |
| BR112023025221A2 (pt) | 2021-06-02 | 2024-02-27 | Astellas Pharma Inc | Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
| WO2025207099A1 (en) | 2024-03-28 | 2025-10-02 | Astellas Pharma Inc. | Ppar-delta inhibitors for preventing post-operative atrial fibrillation |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4228281A (en) | 1977-09-23 | 1980-10-14 | Ciba-Geigy Corporation | Dicarboxylic acids containing triazine rings |
| DE4123341A1 (de) | 1991-07-15 | 1993-01-21 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| NZ514453A (en) | 1999-02-26 | 2003-04-29 | Merck & Co Inc | Novel sulfonamide compounds and uses thereof |
| GB9919413D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| ATE447557T1 (de) | 2000-08-17 | 2009-11-15 | Pfizer Ltd | Substitutuierte imidazole als tafia inhibitoren |
| CN100457730C (zh) * | 2002-08-29 | 2009-02-04 | 默克公司 | 具有抗糖尿病活性的吲哚化合物 |
| US7820682B2 (en) | 2002-10-03 | 2010-10-26 | Ono Pharmaceutical Co., Ltd. | LPA receptor antagonist |
| WO2004060367A1 (en) | 2002-12-30 | 2004-07-22 | Fujisawa Pharmaceutical Co., Ltd. | Imidazole and triazole derivatives useful as selective cox-1 inhibitors |
| MXPA06003357A (es) | 2003-09-26 | 2006-06-08 | Japan Tobacco Inc | Metodo para inhibir la produccion de lipoproteina remanente. |
| BRPI0515140A (pt) | 2004-09-06 | 2008-07-08 | Hoffmann La Roche | derivados de benzamidina de 4-aminometila e seu emprego como inibidores do fator viia |
| CA2597148A1 (en) | 2005-02-15 | 2007-03-15 | F. Hoffmann-La Roche Ag | Amide derivatives as ppar activators |
| BRPI0615948A2 (pt) | 2005-09-07 | 2011-05-31 | Plexxikon Inc | composto ativo de ppar, sua composição, seu kit e seu uso |
| NZ569329A (en) | 2006-01-30 | 2011-09-30 | Transtech Pharma Inc | Substituted imidazole derivatives and their use as PTPase inhibitors |
| MX2008012404A (es) | 2006-03-28 | 2008-10-09 | Novartis Ag | Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g. |
| CN101466687B (zh) | 2006-04-18 | 2012-04-11 | 日本化学医药株式会社 | 过氧化物酶体增殖剂激活受体δ的激活剂 |
| DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| CN101085772A (zh) | 2006-06-07 | 2007-12-12 | 上海艾力斯医药科技有限公司 | 一类具有PPARγ激动剂活性的化合物及其应用 |
| EP2128138A1 (en) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
| KR20080082541A (ko) | 2007-03-07 | 2008-09-11 | 동아제약주식회사 | 퍼옥시좀 증식자-활성화 감마 수용체를 조절하는 신규한페닐프로판산 유도체의 제조방법 및 약학적 용도 |
| JP2008285452A (ja) | 2007-05-21 | 2008-11-27 | Ono Pharmaceut Co Ltd | ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬 |
| CA2710764A1 (en) | 2007-12-28 | 2009-07-09 | The Salk Institute For Biological Studies | Methods for enhancing muscle performance and tone |
| JP5895104B2 (ja) | 2012-08-28 | 2016-03-30 | コチ・ウニヴェルシテシＫｏｃ Ｕｎｉｖｅｒｓｉｔｅｓｉ | 骨板 |
| EP2981522A4 (en) | 2013-04-05 | 2016-08-31 | Salk Inst For Biological Studi | PPAR AGONISTS |
| WO2015035171A1 (en) | 2013-09-09 | 2015-03-12 | High Point Pharmaceuticals, Llc | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
| US20170305894A1 (en) | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| EA037371B1 (ru) | 2015-10-07 | 2021-03-19 | Митобридж, Инк. | Агонисты ppar, соединения, фармацевтические композиции и способы их применения |
| US11358954B2 (en) | 2016-04-13 | 2022-06-14 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| ES2887008T3 (es) * | 2016-10-05 | 2021-12-21 | Mitobridge Inc | Formas cristalinas y de sal de compuestos agonistas del PPAR |
| ES2859487T3 (es) | 2016-10-05 | 2021-10-04 | Mitobridge Inc | Métodos para tratar las lesiones renales agudas |
| SMT202100321T1 (it) * | 2016-12-30 | 2021-07-12 | Mitobridge Inc | Inibitori della poli-adp ribosio polimerasi (parp) |
-
2016
- 2016-10-05 EA EA201890776A patent/EA037371B1/ru unknown
- 2016-10-05 WO PCT/US2016/055521 patent/WO2017062468A1/en not_active Ceased
- 2016-10-05 KR KR1020217032197A patent/KR102667386B1/ko active Active
- 2016-10-05 BR BR112018006866-7A patent/BR112018006866B1/pt active IP Right Grant
- 2016-10-05 HU HUE16785611A patent/HUE058154T2/hu unknown
- 2016-10-05 MX MX2020011099A patent/MX392524B/es unknown
- 2016-10-05 SG SG10201906400SA patent/SG10201906400SA/en unknown
- 2016-10-05 EP EP20193960.0A patent/EP3770146B1/en active Active
- 2016-10-05 MA MA052648A patent/MA52648A/fr unknown
- 2016-10-05 PT PT167856111T patent/PT3359528T/pt unknown
- 2016-10-05 ES ES20193962T patent/ES2949852T3/es active Active
- 2016-10-05 ES ES20193960T patent/ES2988059T3/es active Active
- 2016-10-05 CN CN202110284826.5A patent/CN113004205B/zh active Active
- 2016-10-05 CO CONC2018/0004473A patent/CO2018004473A2/es unknown
- 2016-10-05 KR KR1020187012860A patent/KR102667385B1/ko active Active
- 2016-10-05 EP EP20193962.6A patent/EP3795566B1/en active Active
- 2016-10-05 UA UAA201802841A patent/UA122237C2/uk unknown
- 2016-10-05 CA CA3000431A patent/CA3000431A1/en active Pending
- 2016-10-05 PL PL16785611T patent/PL3359528T3/pl unknown
- 2016-10-05 JP JP2018538052A patent/JP6657413B2/ja active Active
- 2016-10-05 MY MYPI2018000444A patent/MY203081A/en unknown
- 2016-10-05 AU AU2016333963A patent/AU2016333963C1/en active Active
- 2016-10-05 EP EP16785611.1A patent/EP3359528B1/en active Active
- 2016-10-05 ES ES16785611T patent/ES2906379T3/es active Active
- 2016-10-05 CN CN202110286947.3A patent/CN113024467B/zh active Active
- 2016-10-05 MX MX2018004295A patent/MX380281B/es unknown
- 2016-10-05 US US15/766,455 patent/US10399958B2/en active Active
- 2016-10-05 MX MX2020011100A patent/MX392523B/es unknown
- 2016-10-05 DK DK16785611.1T patent/DK3359528T3/da active
- 2016-10-05 MA MA052098A patent/MA52098A/fr unknown
- 2016-10-05 CN CN201680057879.0A patent/CN108349904B/zh active Active
- 2016-10-06 JO JOP/2016/0217A patent/JO3738B1/ar active
- 2016-10-07 TW TW108144723A patent/TWI742479B/zh active
- 2016-10-07 TW TW108133069A patent/TWI730408B/zh active
- 2016-10-07 TW TW105132668A patent/TWI730006B/zh active
-
2018
- 2018-03-19 IL IL258225A patent/IL258225B/en unknown
- 2018-03-27 ZA ZA2018/02029A patent/ZA201802029B/en unknown
- 2018-04-06 PH PH12018500762A patent/PH12018500762A1/en unknown
-
2019
- 2019-07-15 US US16/510,976 patent/US10479775B1/en active Active
- 2019-11-13 US US16/682,676 patent/US10906885B2/en active Active
- 2019-12-18 AU AU2019283837A patent/AU2019283837B2/en active Active
-
2020
- 2020-02-03 JP JP2020016147A patent/JP6866514B2/ja active Active
- 2020-06-15 IL IL275387A patent/IL275387B/en unknown
- 2020-06-15 IL IL275392A patent/IL275392B/en unknown
- 2020-06-18 ZA ZA2020/03662A patent/ZA202003662B/en unknown
- 2020-06-18 ZA ZA2020/03663A patent/ZA202003663B/en unknown
- 2020-06-18 ZA ZA2020/03664A patent/ZA202003664B/en unknown
- 2020-09-14 JO JOJO/P/2020/0231A patent/JOP20200231B1/ar active
- 2020-09-14 JO JOJO/P/2020/0230A patent/JOP20200230B1/ar active
- 2020-12-02 AU AU2020281069A patent/AU2020281069B2/en active Active
-
2021
- 2021-01-29 US US17/162,157 patent/US11578052B2/en active Active
-
2023
- 2023-02-13 US US18/108,785 patent/US20230373948A1/en not_active Abandoned
-
2024
- 2024-01-25 US US18/422,793 patent/US20240417383A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534355A5 (enExample) | ||
| JP2020075939A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2019509276A5 (enExample) | ||
| JP2017508782A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| RU2016119519A (ru) | Соединения гетероарила в качестве ингибиторов btk и их применение | |
| JP2020502111A5 (enExample) | ||
| JP2013528640A5 (enExample) | ||
| JP2011529049A5 (enExample) | ||
| RU2016141934A (ru) | Ингибиторы циклин-зависимой киназы 7 (cdk7) | |
| JP2016531126A5 (enExample) | ||
| JP2015520140A5 (enExample) | ||
| JP2016513661A5 (enExample) | ||
| JP2010525056A5 (enExample) | ||
| JP2013544860A5 (enExample) | ||
| JP2017537949A5 (enExample) | ||
| JP2017501237A5 (enExample) | ||
| JP2017517512A5 (enExample) | ||
| JP2018515525A5 (enExample) | ||
| JP2017517538A5 (enExample) | ||
| JP2016512227A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2017526724A5 (enExample) |